{"id":97674,"date":"2025-12-05T07:36:35","date_gmt":"2025-12-05T07:36:35","guid":{"rendered":"https:\/\/www.europesays.com\/se\/97674\/"},"modified":"2025-12-05T07:36:35","modified_gmt":"2025-12-05T07:36:35","slug":"novo-nordisk-oppna-for-att-fortsatta-utveckla-ozempic-for-alzheimers-bn","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/se\/97674\/","title":{"rendered":"Novo Nordisk \u00f6ppna f\u00f6r att forts\u00e4tta utveckla Ozempic f\u00f6r Alzheimers &#8211; BN"},"content":{"rendered":"<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Danska l\u00e4kemedelsbolaget Novo Nordisk \u00e4r fortsatt \u00f6ppna f\u00f6r att genomf\u00f6ra ytterligare arbete med sin pillerversion av Ozempic f\u00f6r Alzheimers sjukdom. Det efter tv\u00e5 misslyckade studier, skriver Bloomberg News.\n <\/p>\n<p>Novo Nordisk uppger att patienterna visade en biologisk respons inom ett f\u00e5tal omr\u00e5den trots att de inte uppvisade n\u00e5gon kognitiv f\u00f6rb\u00e4ttring.\n <\/p>\n<p>L\u00e4karna s\u00e5g minskningar p\u00e5 10 procent eller mindre i ett f\u00e5tal biomark\u00f6rer f\u00f6r neurodegeneration, inflammation och tau i tv\u00e5 studier av Rybelsus, men ingen f\u00f6r\u00e4ndring i majoriteten av de 30 analyserade mark\u00f6rerna.\n <\/p>\n<p>L\u00e4kemedlet misslyckades samtidigt med att bromsa utvecklingen av Alzheimers sjukdom i studier med \u00f6ver 3 500 patienter. Studierna var ett f\u00f6rs\u00f6k att bredda anv\u00e4ndningen av semaglutid bortom diabetes och fetma.<br \/>\n <br class=\"col-start-2\"\/><\/p>\n<p class=\"font-sans text-base text-text-main dark:text-text-main-dark font-normal leading-[1.4]\">Nils Lolk<br \/>\n <br class=\"col-start-2\"\/><br \/>\n Nyhetsbyr\u00e5n Finwire<\/p>\n","protected":false},"excerpt":{"rendered":"Danska l\u00e4kemedelsbolaget Novo Nordisk \u00e4r fortsatt \u00f6ppna f\u00f6r att genomf\u00f6ra ytterligare arbete med sin pillerversion av Ozempic f\u00f6r&hellip;\n","protected":false},"author":2,"featured_media":77249,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[65],"tags":[72,70,71,34,31,33,32,30],"class_list":{"0":"post-97674","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-ekonomi","8":"tag-business","9":"tag-economy","10":"tag-ekonomi","11":"tag-se","12":"tag-svenska","13":"tag-sverige","14":"tag-sweden","15":"tag-swedish"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@se\/115665815623381449","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/97674","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/comments?post=97674"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/posts\/97674\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media\/77249"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/media?parent=97674"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/categories?post=97674"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/se\/wp-json\/wp\/v2\/tags?post=97674"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}